• Galcanezumab effectively reduced weekly cluster headache attacks

    19 days ago - By Healio

    SAN FRANCISCO - Galcanezumab significantly reduced cluster headache attacks within the first 3 weeks of therapy, according to phase 3 study results presented at the American Headache Society Annual Scientific Meeting.
    Galcanezumab also demonstrated a similar safety profile to placebo except for injection site pain, according to the results.
    “This was uncharted, because cluster headache has not really been studied in a double-blind, placebo-controlled fashion for years,” Sheena K. Aurora, MD, an adjunct clinical associate professor of anesthesiology, perioperative and pain
    Read more ...